Thanks Greg Glasgow for putting this nice article out about our research project funded by American Cancer Society news.cuanschutz.edu/cancer-center/…

Our paper is out today studying ex vivo sensitivity of samples from patients with daratumumab-refractory multiple myeloma. @Lauren_Reiman Zachary Walker CD38 Antibody Re-treatment in Daratumumab-Refractory Multiple Myeloma After Time on Other Therapies ashpublications.org/bloodadvances/…

Nothing says 'I could use a beer (and networking!)' like the holiday season! Please join us for our next BBHH on Dec 14th at Ursula Brewery from 5-7pm. Sponsored by VWR + ProteinSimple. See you there!

See you on Thursday for our next RIP! Alana (Keller) Hoey, PhD Daniel Sherbenou, MD, PhD Sana Karam, MD, PhD #BestYouCANB

CU MONDAY #ASH23 Dec 11-MONDAY! Angelo D'Alessandro 10:30am | Rm 33-SD Conv Ctr manalikamdar 10:30am | Great Hall B-Manchester Grd Hyatt Alana (Keller) Hoey, PhD 6pm | poster Halls G-H, SD Conv Ctr Cassandra Duarte 6pm | poster☝️ Kellen Gil 6pm | poster☝️ Marc Schwartz 6pm | poster☝️

Loved getting to talk about my research in the Daniel Sherbenou, MD, PhD lab and catching up with friends at #ASH2023 ! (Thanks Francesca Cendali for the pic:)

Ex Vivo Screening Comparing Elranatamab Effectiveness Before and After CAR-T. Shout out to ASH abstract lead author Alana (Keller) Hoey, PhD myeloma.org/videos/bcmaxcd…

Excited to share my preclinical characterization of a CD38/CD28xCD3 T cell engaging antibody! Thank you to Daniel Sherbenou, MD, PhD and lab for the support! aacrjournals.org/cancerrescommu…

Just published: #ExVivo Efficacy of SAR442257 anti-CD38 Trispecific T Cell Engager in #MultipleMyeloma Relapsed After Daratumumab and BCMA Targeted Therapies, by Alana (Keller) Hoey, PhD et al. bit.ly/431CyaA CU Anschutz Medical Campus #mmsm #openaccess

We often talk about recycling CD38s after BCMA CAR-T failure in #MMsm... vs going to T-cell redirection with a different pathway like GPRC5D. But maybe we can do it all at the same time: CD38 targeting and T-cell redirection! Great work by Alana (Keller) Hoey, PhD Daniel Sherbenou, MD, PhD!

CONGRATS to Dr. Lorraine Davis in the Daniel Sherbenou, MD, PhD lab for successfully defending her thesis today! So proud of all of your accomplishments!! #BestYouCANB

Absolutely nailed it Lorraine Davis I’m so incredibly proud of all you have accomplished 🥹

#ExVivo Efficacy of SAR442257 anti-CD38 Trispecific T Cell Engager in #MultipleMyeloma Relapsed After Daratumumab and BCMA Targeted Therapies, by Alana (Keller) Hoey, PhD et al. bit.ly/43qaZbp CU Anschutz Medical Campus #mmsm #openaccess

Out Yesterday! Lorraine Davis found that most samples from IMiD Refractory MM have IMiD-induced degradation of Ikaros left INTACT. But MYC dependence remained and its Inhibition was effective treatment in T Cell dependent manner aacrjournals.org/clincancerres/…

Mark your calendars for Alana Keller's thesis defense! Alana (Keller) Hoey, PhD Daniel Sherbenou, MD, PhD #BestYouCANB

Our ASH abstract describing a new CD45+LAG-3+ phenotype displayed by myeloma cells persisting after T cell redirection therapies is now live! ash.confex.com/ash/2024/webpr…

Mark your calendar for Alana Keller’s thesis defense next Tuesday! Alana (Keller) Hoey, PhD Daniel Sherbenou, MD, PhD #BestYouCANB

CONGRATS to Dr. Alana Keller Hoey for successfully defending her thesis today! Way to go Dr. Keller Hoey! #BestYouCANB Alana (Keller) Hoey, PhD Daniel Sherbenou, MD, PhD

My-DST result correlates with clinic response in prospective clinical trial #ASH24 #MMSM

Novel phenotype of MM cells escaping CART and bispecifics #ASH24 #MMSM